[1]唐晓鹏,赵洪雯,余荣杰,等.小剂量干扰素α联合利巴韦林治疗肾移植术后继发丙型病毒性肝炎患者的疗效观察[J].第三军医大学学报,2008,30(02):117-119.
 TANG Xiao-peng,ZHAO Hong-wen,YU Rong-jie,et al.Treatment of hepatitis C after kidney transplantation with combined interferon-α and Ribovirin[J].J Third Mil Med Univ,2008,30(02):117-119.
点击复制

小剂量干扰素α联合利巴韦林治疗肾移植术后继发丙型病毒性肝炎患者的疗效观察(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
30卷
期数:
2008年第02期
页码:
117-119
栏目:
专题报道
出版日期:
2008-01-30

文章信息/Info

Title:
Treatment of hepatitis C after kidney transplantation with combined interferon-α and Ribovirin
作者:
唐晓鹏赵洪雯余荣杰吴雄飞
第三军医大学西南医院肾科
Author(s):
TANG Xiao-peng ZHAO Hong-wen YU Rong-jie WU Xiong-fei
Department of Kidney, Southwest Hospital, Third Military Medical University
关键词:
干扰素α利巴韦林丙肝肾移植
Keywords:
interferon α Ribovirin hepatitis C renal transplantation
分类号:
R512.630.5;R699.2;R978.7
文献标志码:
A
摘要:
目的 观察小剂量干扰素α联合利巴韦林对肾移植术后继发丙型病毒性肝炎患者的疗效及安全性。 方法 采用小剂量干扰素α 50 μg每周1次皮下注射,同时口服利巴韦林600 mg/d治疗5例肾移植术后继发丙型病毒性肝炎患者,并每月复查血常规、肝功能、肾功能和HCV-RNA。  结果 在治疗12周后,有4例出现血清ALT转为正常,HCV-RNA阴性(<100拷贝/ml)的早期应答,在治疗结束时这些患者出现完全应答,1例患者出现部分应答;治疗过程中,5例患者血肌酐均在正常范围内波动,并未见急性排斥反应;副反应主要为不同程度的白细胞、血红蛋白降低及低热、肌痛,但均未影响治疗。  结论 小剂量干扰素α联合利巴韦林治疗肾移植术后继发丙型病毒性肝炎具有较好的临床疗效,未诱发移植肾排斥反应,副反应较轻,值得临床进一步使用。
Abstract:
Objective To investigate the treatment and safety of interferon α plus Ribovirin for chronic hepatitis C after kidney transplantation.   Methods Five patients with chronic hepatitis C after kidney transplantation were administered with interferon α (50 μg) subcutaneously once a week, plus Ribovirin (600 mg) orally once daily. The levels of HCV-RNA, ALT and serum creatinine in patients’ serum were monitored monthly.   Results Four in 5 patients presented normal ALT and negative HCV-RNA in serum 12 weeks after treatment, and obtained sustained viral response 24 weeks after interferon α plus Ribovirin therapy. During treatment, renal graft rejection did not occur. The most frequent side-effects were the decrease of leukocyte and hemoglobin, myalgia and fever, but did not influence the course of treatment.   Conclusion Combination of interferon α with Ribovirin can be a valid therapeutic option in renal transplant recipients with hepatitis C, and shows no influence on the renal function.

参考文献/References:

唐晓鹏,赵洪雯,余荣杰,等. 小剂量干扰素α联合利巴韦林治疗肾移植术后继发丙型病毒性肝炎患者的疗效观察[J].第三军医大学学报,2008,30(2):117-119.

相似文献/References:

[1]周娟,崔玉霞,杨锡强,等.特异性反义寡核苷酸抗小鼠呼吸道合胞病毒感染的研究[J].第三军医大学学报,2007,29(02):112.
 ZHOU Juan,CUI Yu-xia,YANG Xi-qiang,et al.Study on specific antisense oligonucleotide against respiratory syncytial virus in mice[J].J Third Mil Med Univ,2007,29(02):112.
[2]何长龙,吴全新,况雪梅,等.聚乙二醇干扰素联合利巴韦林治疗HCV 6型感染者的临床疗效回顾性观察研究[J].第三军医大学学报,2015,37(12):1252.
 He Changlong,Wu Quanxin,Kuang Xuemei,et al.Clinical efficacy of pegylated interferon plus ribavirin therapy for patients infected with hepatitis C virus genotype 6: a retrospective study[J].J Third Mil Med Univ,2015,37(02):1252.

更新日期/Last Update: 2008-04-30